Cybin Inc
F:R7E1
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
There is not enough data to reliably calculate the intrinsic value of R7E1.
The Intrinsic Value is calculated as the average of DCF and Relative values:
| US |
|
Eli Lilly and Co
NYSE:LLY
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Cybin is highly reliant on successful trial outcomes for CYB003 and other deuterated psilocybin analogs, meaning any clinical setbacks or prolonged timelines could significantly undermine investor confidence.
Cybin’s leading candidate, CYB003, is progressing in clinical trials and, if approved, could position the company at the forefront of next-generation psychedelic treatments for major depressive and addiction disorders.
Revenue & Expenses Breakdown
Cybin Inc
Balance Sheet Decomposition
Cybin Inc
| Current Assets | 143.7m |
| Cash & Short-Term Investments | 118.7m |
| Receivables | 4.1m |
| Other Current Assets | 20.9m |
| Non-Current Assets | 67.2m |
| PP&E | 82k |
| Intangibles | 67.1m |
| Current Liabilities | 14.6m |
| Accounts Payable | 14.6m |
| Non-Current Liabilities | 44.5m |
| Long-Term Debt | 44.5m |
Free Cash Flow Analysis
Cybin Inc
| CAD | |
| Free Cash Flow | CAD |
Earnings Waterfall
Cybin Inc
|
Revenue
|
0
CAD
|
|
Operating Expenses
|
-147.4m
CAD
|
|
Operating Income
|
-147.4m
CAD
|
|
Other Expenses
|
24.5m
CAD
|
|
Net Income
|
-122.9m
CAD
|
R7E1 Profitability Score
Profitability Due Diligence
Cybin Inc's profitability score is hidden . The higher the profitability score, the more profitable the company is.
Score
Cybin Inc's profitability score is hidden . The higher the profitability score, the more profitable the company is.
R7E1 Solvency Score
Solvency Due Diligence
Cybin Inc's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Score
Cybin Inc's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
R7E1 Price Targets Summary
Cybin Inc
Dividends
Current shareholder yield for CYBN is hidden .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?